CVS Health Corp (CVS)
49.56  -0.02 (-0.04%)

CVS Health Corp is a diversified healthcare company that operates a vast network of retail pharmacies, providing prescription medications, over-the-counter products, and health and wellness services. In addition to its retail operations, CVS Health also offers pharmacy benefit management services, helping manage prescription drug costs for businesses and health plans. The company is involved in providing health insurance and health services through its various divisions, including a growing presence in digital health solutions and immunization services. By integrating pharmacy services with healthcare delivery, CVS Health aims to enhance patient care and improve health outcomes across the communities it serves.

SummaryNewsPress ReleasesChartHistorical
CVS Health Hits 11-Year Low; PBM Legislation Could Slash Earnings By 50%, Says Analystinvestors.com
New bipartisan legislation targets pharmacy benefit managers.
Via Investor's Business Daily · December 12, 2024
Joe Rogan On Public Sympathy For UnitedHealthcare CEO Murder Suspect: Health Insurance A 'Dirty, Dirty Business'benzinga.com
Joe Rogan stopped short of offering any sympathy for the death of UnitedHealthcare CEO Brian Thompson with criticism of the health insurance sector.
Via Benzinga · December 12, 2024
Stock Of The Day: Historic Technical Analysis Lesson In CVSbenzinga.com
'Market Memory' means that important price levels can stay intact for weeks, months, or even years. The chart of CVS proves this.
Via Benzinga · December 12, 2024
Why UnitedHealth Group Stock Was Falling Todayfool.com
Via The Motley Fool · December 11, 2024
Bipartisan Lawmakers Aim To Break Up Health Care Giants With New Legislationbenzinga.com
Pharmacy-benefit managers (PBMs) have been scrutinized for their role in drug distribution for years. Now a bipartisan group of lawmakers is threatening to break up the companies behind these so-called drug middlemen.
Via Benzinga · December 11, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · December 11, 2024
What the Options Market Tells Us About CVS Healthbenzinga.com
Via Benzinga · December 11, 2024
Is CVS Health Stock a Buy?fool.com
Via The Motley Fool · December 2, 2024
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · December 10, 2024
What’s Behind These 3 Recent Analyst Stock Upgrades?
Three recent analyst ratings go beyond the consensus, making them a much more significant move for Wall Street analysts to consider.
Via MarketBeat · December 8, 2024
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 7talkmarkets.com
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 2-6, 2024.
Via Talk Markets · December 7, 2024
Blue Shield's $500 Million Drug Savings Initiative With Amazon Pharmacy Can Potentially Launch In Januarybenzinga.com
Blue Shield of California launches its Pharmacy Care Reimagined Initiative with Amazon Pharmacy and Abarca in January, aiming to save $500 million annually in drug costs.
Via Benzinga · December 6, 2024
Key Takeaways From CVS Health Analyst Ratingsbenzinga.com
Via Benzinga · December 3, 2024
CVS Health's Options: A Look at What the Big Money is Thinkingbenzinga.com
Via Benzinga · November 29, 2024
(CVS) - Analyzing CVS Health's Short Interestbenzinga.com
Via Benzinga · November 21, 2024
Is CVS Health Stock an Underrated Buy?fool.com
Via The Motley Fool · November 20, 2024
UnitedHealthcare Faces Scrutiny Amid CEO's Tragic Death, Industry Criticismbenzinga.com
UnitedHealthcare's claim denial practices are under scrutiny following the murder of CEO Brian Thompson, with criticism over its profit-driven approach to care.
Via Benzinga · December 6, 2024
13 Healthcare Sector Stocks With Healthy Valuationtalkmarkets.com
We are looking for value in the Healthcare Sector because we are still in a strong bull market that has been not only one of the longest on record, but also has seen the S&P 500 get to one of its lofty valuations ever.
Via Talk Markets · December 5, 2024
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Marketinvestors.com
An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity.
Via Investor's Business Daily · December 5, 2024
This Citigroup Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesdaybenzinga.com
Via Benzinga · December 3, 2024
Pharma-Grade Cannabis Could Hit Walgreens & CVS—But Can The Industry Survive The FDA?benzinga.com
As the formal review process for rescheduling cannabis unfolds, industry players are closely watching its potential to transform the sector.
Via Benzinga · November 28, 2024
3 Key Analyst Upgrades: Why These Stocks Are Getting a Boost
Retail investors have a chance to break down the reasons behind the latest analyst upgrades and why they're being made in these three stocks.
Via MarketBeat · November 26, 2024
Billionaire Israel Englander Bought This High-Yield Dividend Stock Hand Over Fist in Q3. Should You Buy It Too?fool.com
Via The Motley Fool · November 25, 2024
Palantir Price Target Raised To $75 By Dan Ives Amid 288% YTD Surge: Analyst Calls 2025 A 'Primetime' Year For AIbenzinga.com
Wedbush Securities has issued an endorsement of the artificial intelligence software sector, with Managing Director Dan Ives predicting that 2025 will be a pivotal year for AI implementation across the industry. This comes as Palantir Technologies Inc. continues its remarkable ascent, having surged 288% year-to-date.
Via Benzinga · November 24, 2024
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yieldsbenzinga.com
Via Benzinga · November 21, 2024